Paz-Arez L, Villegas A, Daniel D, et al. LBA1_PR - PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC. ESMO 2017 Congress; LBA1_PR.
FDA keurt pembrolizumab goed voor adjuvante behandeling stadium IIB/IIC-melanoom
dec 2021 | Dermato-oncologie, Immuuntherapie